← Russell 3000 cross-section

ABT ABBOTT LABORATORIES

Trailing twelve months to 2026-03-31 · as filed 2026-04-29, not restated
Healthcare

Scale

Market cap
$193.6bn
Revenue TTM
$45.1bn
Net income TTM
$6.3bn
Free cash flow
$7.4bn
Composite score
50.2
Sector rank
#60

Valuation

P / E
30.8
EV / EBITDA
19.9
EV / sales
4.8
FCF yield
3.81%
Earnings yield vs 10-yr
-1.49pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
13.9%
EBITDA margin
24.1%
ROE
12.1%
ROIC
10.4%
Revenue growth
6.6%

Insider activity, last 90 days

Net open-market
$-46.67m
Buyers
1
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Percent changes are versus the prior year and are based on unrounded numbers. ___________________________________ The 12.2 percent increase in total net sales during the second quarter of 2026, excluding the impact of foreign exchange, was driven by the acquisition of Exact Sciences Corporation (Exact Sciences) and high single-digit growth in Medical Devices and Established Pharmaceutical Products, partially offset by lower sales in Nutritional Products. On a reported basis, net sales were favorably impacted by foreign exchange as the relatively weaker U.S. dollar increased total international sales by 1.3 percent and total sales by 0.8 percent. …ABBOTT LABORATORIES, 10-Q, period ended 2026-06-30, filed 2026-07-28

Read the full passage →